Wheeler Bio, a contract development and manufacturing organization (CDMO) specializing in antibody-based therapies, has secured $35 million in an oversubscribed Series A-1 financing round. The investment was led by Alloy Therapeutics and Echo Investment Capital, with additional support from Mitsubishi
Wheeler Bio has announced the appointment of Patrick Lucy as its new Chief Executive Officer, signalling a key leadership shift as the company moves towards expanding its contract development and manufacturing (CDMO) capabilities. With more than 32 years of experience
Wheeler Bio, a contract development and manufacturing organisation (CDMO), has announced a strategic expansion by licensing ATUM’s miFuc™ platform. The technology enables the production of recombinant proteins, particularly afucosylated antibodies, that offer improved therapeutic windows and increased antibody-dependent cellular cytotoxicity
Wheeler Bio Contract Manufacturing & Development (CDMO) Profile Niche Biopharmaceutical CDMO. Wheeler Bio brings biologics drug innovators, discovery CROs, and CDMOs together to solve an outdated industry bottleneck with a unique partnering model, built on shared success and lasting collaborations.
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
